Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data

Simply Wall St.06-19

Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644405590?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-19 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644405590","market":"hk","top_or_hot":-1,"title":"Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data","media":"Simply Wall St.","content":"<div>\n<p>Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-stock-could-be-512-undervalued-after-equ\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-19 13:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-stock-could-be-512-undervalued-after-equ><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-stock-could-be-512-undervalued-after-equ\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-stock-could-be-512-undervalued-after-equ","article_id":"2644405590","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-stock-could-be-512-undervalued-after-equ","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644405590","pubTimestamp":1781846893,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept data for its in vivo CAR T program LB2501.\nSee our latest analysis for Legend Biotech.\nLegend Biotech’s share price has been volatile around these updates, falling 16.7% on the day and 23.0% over the past week, yet still posting a 60.4% 90 day share price return while the 3 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","LEGN":"传奇生物","EQR":"资产住宅公司","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","BK4215":"住宅房地产投资信托","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"在股权融资和LB2501数据后，传奇生物(LEGN)股票可能被低估51.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"LEGN":1.5,"XBI":1.5},"content_text":"Legend Biotech (LEGN) has attracted fresh attention after completing a follow on equity offering of American Depositary Shares worth about US$226 million, and releasing early clinical proof of concept data for its in vivo CAR T program LB2501. See our latest analysis for Legend Biotech. Legend Biotech’s share price has been volatile around these updates, falling 16.7% on the day and 23.0% over the past week, yet still posting a 60.4% 90 day share price return while the 3 year total shareholder return is down 62.8%. If you are looking beyond Legend Biotech to other potential opportunities in healthcare and AI driven therapies, this could be a good time to scan 41 healthcare AI stocks. With Legend Biotech now trading well below its recent offer price yet still showing strong 90 day gains and an intrinsic value estimate above the market price, investors have to ask: is this pullback a buying opportunity, or is future growth already priced in? AdvertisementMost Popular Narrative: 51.2% Undervalued The most followed narrative on Legend Biotech pegs fair value around $57.24, a clear gap to the last close at $27.93, and builds a case on execution in multiple myeloma and cash flow potential under a 7.31% discount rate.  Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.  Read the complete narrative. Want to see what underpins that valuation gap on Legend Biotech? The narrative leans on aggressive revenue scaling, rising margins, and a future earnings multiple that assumes real staying power. Result: Fair Value of $57.24 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Legend Biotech narrative could be challenged if heavy reliance on CARVYKTI, intense competition, or ongoing high R&D and manufacturing costs weigh on long term profitability. Find out about the key risks to this Legend Biotech narrative. Next Steps With mixed sentiment around Legend Biotech, this is a moment to move quickly, review the numbers yourself, and decide what really matters. To weigh both the concerns and the potential upside in context, start with the 3 key rewards and 1 important warning sign. Looking for more investment ideas beyond Legend Biotech? If Legend Biotech has sharpened your focus on where capital goes next, use this moment to scout fresh ideas instead of waiting on the sidelines.  Spot potential mispricings by scanning companies that look cheap on quality and value metrics using the 45 high quality undervalued stocks. Prioritize resilience by reviewing businesses that pass strict financial health checks via the solid balance sheet and fundamentals stocks screener (48 results). Get ahead of the crowd by combing through a screener containing 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644405590","isCrawlerRequest":true}